Sinovac Biotech

Sinovac Biotech is a Chinese biopharmaceutical company that specializes in the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines for hepatitis A, hepatitis B, influenza, and COVID-19, among others.

History

Sinovac Biotech was founded in 2001. The company's headquarters are located in Beijing, China. Sinovac's primary focus is on the development and manufacture of vaccines for infectious diseases that present significant health risks in China and globally.

Products

Sinovac's product portfolio includes vaccines for a variety of infectious diseases. These include:

• Healive: A vaccine for hepatitis A
• Bilive: A combined vaccine for hepatitis A and B
• Anflu: A vaccine for influenza
• CoronaVac: A vaccine for COVID-19

CoronaVac

CoronaVac is a COVID-19 vaccine developed by Sinovac. It is an inactivated vaccine, which means it uses a non-infectious version of the coronavirus to stimulate an immune response in the body. CoronaVac has been approved for use in China and several other countries around the world.

Research and Development

Sinovac continues to invest in research and development to create new vaccines and improve existing ones. The company's R&D efforts are primarily focused on infectious diseases that are prevalent in China and other parts of the world.

See Also

• COVID-19 vaccine
• Biopharmaceutical
• Vaccine